ACADIA Pharmaceuticals Inc.
ACAD
Pozycja w akcjach
#4655
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Cena akcji
$18.95
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$3.26B
Zmiana (1 dzień)
-3.86%
Zmiana (1 rok)
-9.29%
Kraj
US
Handel ACADIA Pharmaceuticals Inc. (ACAD)
Kategoria
Healthcare
Marża operacyjna dla ACADIA Pharmaceuticals Inc. (ACAD)
Marża operacyjna na dzień October 2026 TTM: 7.59%
Według najnowszych raportów finansowych i ceny akcji ACADIA Pharmaceuticals Inc., bieżąca marża operacyjna (TTM) wynosi 7.59%. Na koniec 2023 wynosiła -10.10%.
Historia marży operacyjnej dla ACADIA Pharmaceuticals Inc. od 2000 do 2026
Marża operacyjna na koniec każdego roku
| Rok | Marża operacyjna | Zmień |
|---|---|---|
| 2026 (TTM) | 7.59% | -68.51% |
| 2024 | 24.10% | -338.61% |
| 2023 | -10.10% | -76.64% |
| 2022 | -43.23% | 22.81% |
| 2021 | -35.20% | -45.74% |
| 2020 | -64.87% | -10.78% |
| 2019 | -72.71% | -34.23% |
| 2018 | -110.56% | -52.77% |
| 2017 | -234.11% | -85.13% |
| 2016 | -1,574.14% | -99.42% |
| 2015 | -269,855.74% | 247.34% |
| 2014 | -77,691.67% | 2,222.82% |
| 2013 | -3,344.72% | 685.81% |
| 2012 | -425.64% | -61.50% |
| 2011 | -1,105.56% | -3,186.43% |
| 2010 | 35.82% | -105.04% |
| 2009 | -710.55% | -83.13% |
| 2008 | -4,212.45% | 407.95% |
| 2007 | -829.31% | 37.50% |
| 2006 | -603.15% | 84.56% |
| 2005 | -326.81% | -42.34% |
| 2004 | -566.76% | 204.35% |
| 2003 | -186.22% | -7.44% |
| 2002 | -201.19% | -51.10% |
| 2001 | -411.39% | 57.42% |
| 2000 | -261.34% | 0.00% |
Marża operacyjna dla podobnych firm lub konkurentów
| Firma | Marża operacyjna | Różnica w marży operacyjnej | Kraj |
|---|---|---|---|
| 38.59% | -94.92% |
US
|
|
| -149.01% | -119.63% |
US
|
|
| 25.57% | -96.63% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -96.20% |
NL
|
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.